Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of a Human Menopausal Gonadotropin in the Development of Multiple Follicles, Pregnancy, and Cumulative Live Birth as Part of an Assisted Reproductive Technology (ART) Cycle.
Conditions
Interventions
hMG subcutaneous injection
Placebo
Locations
16
United States
HRC Fertility
Encino, California, United States
Illume Fertility
Norwalk, Connecticut, United States
Reproductive Associates of Delaware CCRM
Newark, Delaware, United States
IVF Florida Reproductive Associates
Margate, Florida, United States
Center for Reproductive Medicine
Winter Park, Florida, United States
Reproductive Biology Associates (RBA)
Atlanta, Georgia, United States
Start Date
November 1, 2025
Primary Completion Date
November 1, 2028
Completion Date
November 1, 2028
Last Updated
April 27, 2026
NCT07404969
NCT07185724
NCT07148999
NCT06629766
NCT06636838
NCT06816381
Lead Sponsor
Granata Bio Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions